ClinVar Miner

Submissions for variant NM_001278293.3(ARL6):c.506del (p.Gly169fs)

dbSNP: rs1402463567
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001068039 SCV001233128 pathogenic Bardet-Biedl syndrome 3; Retinitis pigmentosa 55 2023-08-23 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly169 amino acid residue in ARL6. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15314642, 19236846). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 861499). This premature translational stop signal has been observed in individuals with retinitis pigmentosa (Invitae). This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Gly169Alafs*6) in the ARL6 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 18 amino acid(s) of the ARL6 protein.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.